Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, and Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
Department of Clinical Psychology, Radboud University, Nijmegen; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; and Radboudumc Center for Mindfulness, Department of Psychiatry, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Clin Exp Rheumatol. 2023 Aug;41(8):1639-1643. doi: 10.55563/clinexprheumatol/cca0xv. Epub 2023 Apr 19.
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in people with SSc through March 2022.
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analyses included estimated means with 95% CIs for anxiety and depression symptoms pre-COVID-19 for ongoing SPIN Cohort participants and anxiety, depression, loneliness, and fear of COVID-19 for all participants across 28 COVID-19 assessments up to March 2022. We conducted sensitivity analyse including estimating trajectories using only responses from participants who completed >90% of items for ≥21 of 28 possible assessments ("completers") and stratified analyses for all outcomes by sex, age, country, and SSc subtype.
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by mid-2020 compared to pre-COVID-19 and were stable through March 2022. COVID-19 fear started high and decreased. Loneliness did not change across the pandemic. Results were similar for completers and for all subgroups.
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering the pandemic well, but health care providers should be mindful that some individuals may benefit from mental health support.
系统性硬化症 (SSc) 患者在 COVID-19 中易感染，且面临与 COVID-19 风险和保护限制变化相关的挑战。我们评估了截至 2022 年 3 月，SSc 患者的心理健康症状轨迹。
纵向硬皮病患者为中心的干预网络 (SPIN) COVID-19 队列于 2020 年 4 月启动，包括来自正在进行的 SPIN 队列和外部入组者的参与者。分析包括正在进行的 SPIN 队列参与者在 COVID-19 前的焦虑和抑郁症状的估计平均值及其 95%置信区间，以及所有参与者在 28 次 COVID-19 评估中的焦虑、抑郁、孤独和对 COVID-19 的恐惧，直至 2022 年 3 月。我们进行了敏感性分析，包括仅使用完成 >90%的 28 项可能评估中的≥21 项评估的参与者的回复来估计轨迹（“完成者”），以及按性别、年龄、国家和 SSc 亚型对所有结果进行分层分析。
2020 年初，焦虑症状增加，但在 2020 年年中恢复到 COVID-19 前的水平，并在 2022 年 3 月前保持稳定。抑郁症状最初没有变化，但在 2020 年年中与 COVID-19 前相比略低，且在 2022 年 3 月前保持稳定。对 COVID-19 的恐惧开始很高，后来下降。孤独感在整个大流行期间没有变化。完成者和所有亚组的结果相似。
SSc 患者继续面临与持续风险、社会开放和保护限制取消相关的 COVID-19 挑战。总体而言，SSc 患者似乎在应对大流行方面表现良好，但医疗保健提供者应注意，某些个体可能受益于心理健康支持。
